A novel multiplexed immunoassay identifies CEA, IL-8 and prolactin as prospective markers for Dukes’ stages A-D colorectal cancers

Clinical Proteomics

Mark S Baker⁴  Edouard Nice³  Sock-Hwee Tan⁴  Shoba Ranganathan⁵  Md Golam Muktadir²  Abidali Mohamedali⁵  Alamgir Khan¹  Edmond J Breen¹  Gabriella Edfeldt⁶  Simon Fredriksson⁶  Emma Rennel⁶  David Cantor⁴  Harish R Cheruku⁴  Seong Beom Ahn⁴  Mahboob Sadia⁴ 

[1] Australian Proteome Analysis Facility, Macquarie University, Sydney 2109, NSW, Australia;School of Science and Health, University of Western, Sydney, NSW, Australia;Department of Biochemistry and Molecular Biology, Monash University, Clayton Campus, Melbourne 3800, VIC, Australia;Australian School of Advanced Medicine, Faculty of Medicine and Human Sciences, Macquarie University, Rm1, Level 1, 75 Talavera Road, Sydney 2109, NSW, Australia;Department of Chemistry and Biomolecular Sciences, Faculty of Science, Macquarie University, Sydney 2109, NSW, Australia;Olink Bioscience, Dag Hammarskjölds Väg, 54A, Uppsala, 75183, Sweden

关键词: Colorectal cancer;    Plasma biomarker;    Multiplex immunoassay;   

Others  :  1172643
DOI  :  10.1186/s12014-015-9081-x

 received in 2014-10-29, accepted in 2015-03-04,  发布年份 2015

【 摘 要 】

Background

Current methods widely deployed for colorectal cancers (CRC) screening lack the necessary sensitivity and specificity required for population-based early disease detection. Cancer-specific protein biomarkers are thought to be produced either by the tumor itself or other tissues in response to the presence of cancers or associated conditions. Equally, known examples of cancer protein biomarkers (e.g., PSA, CA125, CA19-9, CEA, AFP) are frequently found in plasma at very low concentration (pg/mL-ng/mL). New sensitive and specific assays are therefore urgently required to detect the disease at an early stage when prognosis is good following surgical resection. This study was designed to meet the longstanding unmet clinical need for earlier CRC detection by measuring plasma candidate biomarkers of cancer onset and progression in a clinical stage-specific manner. EDTA plasma samples (1 μL) obtained from 75 patients with Dukes’ staged CRC or unaffected controls (age and sex matched with stringent inclusion/exclusion criteria) were assayed for expression of 92 human proteins employing the Proseek® Multiplex Oncology I proximity extension assay. An identical set of plasma samples were analyzed utilizing the Bio-Plex Pro™ human cytokine 27-plex immunoassay.

Results

Similar quantitative expression patterns for 13 plasma antigens common to both platforms endorsed the potential efficacy of Proseek as an immune-based multiplex assay for proteomic biomarker research. Proseek found that expression of Carcinoembryonic Antigen (CEA), IL-8 and prolactin are significantly correlated with CRC stage.

Conclusions

CEA, IL-8 and prolactin expression were found to identify between control (unaffected), non-malignant (Dukes’ A + B) and malignant (Dukes’ C + D) stages.

【 授权许可】

   
2015 Sadia et al.; licensee BioMed Central.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

【 参考文献 】

• [1]Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin D, Forman D, Bray F: Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. GLOBOCAN 2012, v1.0.
• [2]Dukes CE: The classification of cancer of the rectum. J Pathol Bacteriol 1932, 35:323-32.
• [3]Beattie T: Classification of colorectal cancer to aid the stomal therapy nurse in practice. Journal of Stomal Therapy Australia 2012, 32.
• [4]Peeters M, Price T, Van Laethem JL: Anti-epidermal growth factor receptor monotherapy in the treatment of metastatic colorectal cancer: where are we today? Oncologist 2009, 14:29-39.
• [5]Loberg M, Kalager M, Holme O, Hoff G, Adami HO, Bretthauer M: Long-term colorectal-cancer mortality after adenoma removal. N Engl J Med 2014, 371:799-807.
• [6]Langan RC, Mullinax JE, Raiji MT, Upham T, Summers T, Stojadinovic A, et al.: Colorectal cancer biomarkers and the potential role of cancer stem cells. J Cancer 2013, 4:241-50.
• [7]Heichman KA: Blood-based testing for colorectal cancer screening. Mol Diagn Ther 2014, 18:127-35.
• [8]Duffy MJ, van Dalen A, Haglund C, Hansson L, Klapdor R, Lamerz R, et al.: Clinical utility of biochemical markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines. Eur J Cancer 2003, 39:718-27.
• [9]Ang CS, Rothacker J, Patsiouras H, Gibbs P, Burgess AW, Nice EC: Use of multiple reaction monitoring for multiplex analysis of colorectal cancer-associated proteins in human feces. Electrophoresis 2011, 32:1926-38.
• [10]Nice E: Biomarker discovery and validation: the tide is turning. Expert Rev Proteomics 2013, 10:505-7.
• [11]Lea P, Keystone E, Mudumba S, Kahama A, Ding SF, Hansen J, et al.: Advantages of multiplex proteomics in clinical immunology: the case of rheumatoid arthritis: novel IgXPLEX: planar microarray diagnosis. Clin Rev Allergy Immunol 2011, 41:20-35.
• [12]Assarsson E, Lundberg M, Holmquist G, Bjorkesten J, Bucht Thorsen S, Ekman D, et al.: Homogenous 96-Plex PEA Immunoassay Exhibiting High Sensitivity, Specificity, and Excellent Scalability. PLoS One 2014, 9:e95192.
• [13]Hjelm F, Tran B, Fredriksson S: Sensitive detection of cytokines in 1-[mu]l serum samples using Proseek[reg]. Nat Meth 2011, 8.
• [14]Li D, Chiu H, Gupta V, Chan DW: Validation of a multiplex immunoassay for serum angiogenic factors as biomarkers for aggressive prostate cancer. Clin Chim Acta 2012, 413:1506-11.
• [15]Nielsen HJ, Brunner N, Jorgensen LN, Olsen J, Rahr HB, Thygesen K, et al.: Plasma TIMP-1 and CEA in detection of primary colorectal cancer: a prospective, population based study of 4509 high-risk individuals. Scand J Gastroenterol 2011, 46:60-9.
• [16]Japink D, Leers MP, Sosef MN, Nap M: CEA in activated macrophages. New diagnostic possibilities for tumor markers in early colorectal cancer. Anticancer Res 2009, 29:3245-51.
• [17]National Institutes of Health consensus development conference statement CEA (carcinoembryonic antigen): its role as a marker in the management of cancer. J Ark Med Soc 1981, 78:65-68. (Accessed online: 12th March, 2015).
• [18]CEA (Carcinoembryonic Antigen): Its Role as a Marker in the Management of Cancer. NIH Consens Statement Online 1980 Sep 29-Oct 1 [cited 15/03/12]; 3(7):1-4.
• [19]Ahlemann LM, Staab HJ, Koch HL, Anderer FA: Carcinoembryonic antigen (CEA) measurements as an aid to management of patients with lung cancer treated by radiotherapy. Oncodev Biol Med 1980, 1:143-50.
• [20]Bray PF, Wu JT, Madsen AC: Carcinoembryonic antigen (CEA) assay. In diagnosis and management of cancer. Rocky Mt Med J 1975, 72:21-3.
• [21]Hansen HJ, Snyder JJ, Miller E, Vandevoorde JP, Miller ON, Hines LR, et al.: Carcinoembryonic antigen (CEA) assay. A laboratory adjunct in the diagnosis and management of cancer. Hum Pathol 1974, 5:139-47.
• [22]Peterson JE, Zurakowski D, Italiano JE Jr, Michel LV, Connors S, Oenick M, et al.: VEGF, PF4 and PDGF are elevated in platelets of colorectal cancer patients. Angiogenesis 2012, 15:265-73.
• [23]Liu J, Duan Y, Cheng X, Chen X, Xie W, Long H, et al.: IL-17 is associated with poor prognosis and promotes angiogenesis via stimulating VEGF production of cancer cells in colorectal carcinoma. Biochem Biophys Res Commun 2011, 407:348-54.
• [24]Bunger S, Haug U, Kelly FM, Klempt-Giessing K, Cartwright A, Posorski N, et al.: Toward standardized high-throughput serum diagnostics: multiplex-protein array identifies IL-8 and VEGF as serum markers for colon cancer. J Biomol Screen 2011, 16:1018-26.
• [25]Kirman I, Belizon A, Balik E, Feingold D, Arnell T, Horst P, et al.: Perioperative sargramostim (recombinant human GM-CSF) induces an increase in the level of soluble VEGFR1 in colon cancer patients undergoing minimally invasive surgery. Eur J Surg Oncol 2007, 33:1169-76.
• [26]Malaguarnera L, Imbesi RM, Scuto A, D'Amico F, Licata F, Messina A, et al.: Prolactin increases HO-1 expression and induces VEGF production in human macrophages. J Cell Biochem 2004, 93:197-206.
• [27]Chin KF, Greenman J, Reusch P, Gardiner E, Marme D, Monson J: Changes in serum soluble VEGFR-1 and Tie-2 receptors in colorectal cancer patients following surgical resections. Anticancer Res 2004, 24:2353-7.
• [28]Chin KF, Greenman J, Reusch P, Gardiner E, Marme D, Monson JR: Vascular endothelial growth factor and soluble Tie-2 receptor in colorectal cancer: associations with disease recurrence. Eur J Surg Oncol 2003, 29:497-505.
• [29]Kantola T, Klintrup K, Vayrynen JP, Vornanen J, Bloigu R, Karhu T, et al.: Stage-dependent alterations of the serum cytokine pattern in colorectal carcinoma. Br J Cancer 2012, 107:1729-36.
• [30]TaghipourFardArdekani M, Malekzadeh M, Hosseini SV, Bordbar E, Doroudchi M, Ghaderi A: Evaluation of Pre-Treatment Serum Levels of IL-7 and GM-CSF in Colorectal Cancer Patients. Int J Mol Cell Med 2014, 3:27-34.
• [31]Tilg H, Trehu E, Atkins MB, Dinarello CA, Mier JW: Interleukin-6 (IL-6) as an anti-inflammatory cytokine: induction of circulating IL-1 receptor antagonist and soluble tumor necrosis factor receptor p55. Blood 1994, 83:113-8.
• [32]Ortea I, Roschitzki B, Ovalles JG, Longo JL, de la Torre I, Gonzalez I, et al.: Discovery of serum proteomic biomarkers for prediction of response to infliximab (a monoclonal anti-TNF antibody) treatment in rheumatoid arthritis: an exploratory analysis. J Proteomics 2012, 77:372-82.
• [33]Georgakis A, Kotropoulos C, Xafopoulos A, Pitas I: Marginal median SOM for document organization and retrieval. Neural Netw 2004, 17:365-77.
• [34]Choi JW, Liu H, Shin DH, Yu GI, Hwang JS, Kim ES, et al.: Proteomic and cytokine plasma biomarkers for predicting progression from colorectal adenoma to carcinoma in human patients. Proteomics 2013, 13:2361-74.
• [35]Coghlin C, Murray GI: Progress in the identification of plasma biomarkers of colorectal cancer. Proteomics 2013, 13:2227-8.
• [36]Ellington AA, Kullo IJ, Bailey KR, Klee GG: Antibody-based protein multiplex platforms: technical and operational challenges. Clin Chem 2010, 56:186-93.
• [37]Marianelli P, Bassi Luciani L, Micera S: Electrical potential distribution within the inner ear: a preliminary study for vestibular prosthesis design. Conf Proc IEEE Eng Med Biol Soc 2012, 2012:3017-20.
• [38]Juncker D, Bergeron S, Laforte V, Li H: Cross-reactivity in antibody microarrays and multiplexed sandwich assays: shedding light on the dark side of multiplexing. Curr Opin Chem Biol 2014, 18:29-37.
• [39]Thorsen SB, Lundberg M, Villablanca A, Christensen SL, Belling KC, Nielsen BS, et al.: Detection of serological biomarkers by proximity extension assay for detection of colorectal neoplasias in symptomatic individuals. J Transl Med 2013, 11:253.
• [40]Ward U, Primrose JN, Finan PJ, Perren TJ, Selby P, Purves DA, et al.: The use of tumour markers CEA, CA-195 and CA-242 in evaluating the response to chemotherapy in patients with advanced colorectal cancer. Br J Cancer 1993, 67:1132-5.
• [41]Litvka A, Cercek A, Segal N, Reidy-Lagunes D, Stadler ZK, Yaeger RD, et al.: False-positive elevations of carcinoembryonic antigen in patients with a history of resected colorectal cancer. J Natl Compr Canc Netw 2014, 12:907-13.
• [42]Ning Y, Manegold PC, Hong YK, Zhang W, Pohl A, Lurje G, et al.: Interleukin-8 is associated with proliferation, migration, angiogenesis and chemosensitivity in vitro and in vivo in colon cancer cell line models. Int J Cancer 2011, 128:2038-49.
• [43]Malicki S, Winiarski M, Matlok M, Kostarczyk W, Guzdek A, Konturek PC: IL-6 and IL-8 responses of colorectal cancer in vivo and in vitro cancer cells subjected to simvastatin. J Physiol Pharmacol 2009, 60:141-6.
• [44]Rubie C, Frick VO, Pfeil S, Wagner M, Kollmar O, Kopp B, et al.: Correlation of IL-8 with induction, progression and metastatic potential of colorectal cancer. World J Gastroenterol 2007, 13:4996-5002.
• [45]Fernando RI, Castillo MD, Litzinger M, Hamilton DH, Palena C: IL-8 signaling plays a critical role in the epithelial–mesenchymal transition of human carcinoma cells. Cancer Res 2011, 71:5296-306.
• [46]Waugh DJ, Wilson C: The interleukin-8 pathway in cancer. Clin Cancer Res 2008, 14:6735-41.
• [47]Terada H, Urano T, Konno H: Association of interleukin-8 and plasminogen activator system in the progression of colorectal cancer. Eur Surg Res 2005, 37:166-72.
• [48]Ben-Jonathan N, Liby K, McFarland M, Zinger M: Prolactin as an autocrine/paracrine growth factor in human cancer. Trends Endocrinol Metab 2002, 13:245-50.
• [49]Bhatavdekar JM, Patel DD, Giri DD, Karelia NH, Vora HH, Ghosh N, et al.: Comparison of plasma prolactin and CEA in monitoring patients with adenocarcinoma of colon and rectum. Br J Cancer 1992, 66:977-80.
• [50]Bhatavdekar JM, Patel DD, Chikhlikar PR, Shah NG, Vora HH, Ghosh N, et al.: Ectopic production of prolactin by colorectal adenocarcinoma. Dis Colon Rectum 2001, 44:119-27.
• [51]Neradugomma NK, Subramaniam D, Tawfik OW, Goffin V, Kumar TR, Jensen RA, et al.: Prolactin signaling enhances colon cancer stemness by modulating Notch signaling in a Jak2-STAT3/ERK manner. Carcinogenesis 2014, 35:795-806.
• [52]Sun Q, Sun F, Wang B, Liu S, Niu W, Liu E, et al.: Interleukin-8 promotes cell migration through integrin alphavbeta6 upregulation in colorectal cancer. Cancer Lett 2014, 2:161-74.
• [53]Khan A: Detection and quantitation of forty eight cytokines, chemokines, growth factors and nine acute phase proteins in healthy human plasma, saliva and urine. J Proteomics 2012, 75:4802-19.
• [54]Yamada M, Ichikawa Y, Yamagishi S, Momiyama N, Ota M, Fujii S, et al.: Amphiregulin is a promising prognostic marker for liver metastases of colorectal cancer. Clin Cancer Res 2008, 14:2351-6.
• [55]McCarty MF, Somcio RJ, Stoeltzing O, Wey J, Fan F, Liu W, et al.: Overexpression of PDGF-BB decreases colorectal and pancreatic cancer growth by increasing tumor pericyte content. J Clin Invest 2007, 117:2114-22.
• [56]Galizia G, Orditura M, Romano C, Lieto E, Castellano P, Pelosio L, et al.: Prognostic significance of circulating IL-10 and IL-6 serum levels in colon cancer patients undergoing surgery. Clin Immunol 2002, 102:169-78.
• [57]Rupertus K, Sinistra J, Scheuer C, Nickels RM, Schilling MK, Menger MD, et al.: Interaction of the chemokines I-TAC (CXCL11) and SDF-1 (CXCL12) in the regulation of tumor angiogenesis of colorectal cancer. Clin Exp Metastasis 2014, 31:447-59.
• [58]Kawamura M, Toiyama Y, Tanaka K, Saigusa S, Okugawa Y, Hiro J, et al.: CXCL5, a promoter of cell proliferation, migration and invasion, is a novel serum prognostic marker in patients with colorectal cancer. Eur J Cancer 2012, 48:2244-51.
• [59]Speetjens FM, Kuppen PJ, Sandel MH, Menon AG, Burg D, van de Velde CJ, et al.: Disrupted expression of CXCL5 in colorectal cancer is associated with rapid tumor formation in rats and poor prognosis in patients. Clin Cancer Res 2008, 14:2276-84.
• [60]Dimberg J, Dienus O, Lofgren S, Hugander A, Wagsater D: Expression and gene polymorphisms of the chemokine CXCL5 in colorectal cancer patients. Int J Oncol 2007, 31:97-102.
• [61]Baier PK, Eggstein S, Wolff-Vorbeck G, Baumgartner U, Hopt UT: Chemokines in human colorectal carcinoma. Anticancer Res 2005, 25:3581-4.
• [62]Crittenden M, Gough M, Harrington K, Olivier K, Thompson J, Vile RG: Expression of inflammatory chemokines combined with local tumor destruction enhances tumor regression and long-term immunity. Cancer Res 2003, 63:5505-12.
• [63]Turner PK, Houghton JA, Petak I, Tillman DM, Douglas L, Schwartzberg L, et al.: Interferon-gamma pharmacokinetics and pharmacodynamics in patients with colorectal cancer. Cancer Chemother Pharmacol 2004, 53:253-60.
• [64]Kang M, Edmundson P, Araujo-Perez F, McCoy AN, Galanko J, Keku TO: Association of plasma endotoxin, inflammatory cytokines and risk of colorectal adenomas. BMC Cancer 2013, 13:91.
• [65]Neagu S, Lerescu L, Costea R, Tucureanu C, Caras I, Gangura G, et al.: Salageanu A: [Perioperative immunologic changes in colorectal cancer patients]. Chirurgia (Bucur) 2012, 107:59-65.